The amazing world of Auger electrons

International Journal of Radiation Biology

Volumn 80, Issue 11-12, 2004, Pages 789-803

  Kassis, Amin I ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; FLUOROURACIL; FOLIC ACID; IDOXURIDINE I 123; IDOXURIDINE I 125; INDIUM 111; IODINE 125; METHOTREXATE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AUGER ELECTRON SPECTROSCOPY; CELL LEVEL; COLON CANCER; CONFERENCE PAPER; DOSIMETRY; DRUG EFFICACY; DRUG UPTAKE; ENERGY; HUMAN; IONIZATION; LIVER CANCER; METASTASIS; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RADIATION DOSE; RADIATION HAZARD; RADIATION INJURY;

ANIMALS; CELL PHYSIOLOGY; CELL SURVIVAL; DNA; ELECTRONS; HUMANS; NEOPLASMS; RADIATION DOSAGE; RADIOBIOLOGY; RADIOMETRY;

ANIMALIA;

EID: 12344332475     PISSN: 09553002     EISSN: None     Source Type: Journal    
DOI: 10.1080/09553000400017663     Document Type: Conference Paper

References (183)

1. ADELSTEIN, S. J., KASSIS, A. I. and SASTRY, K. S. R., 1986, Cellular vs. organ approaches to dose estimates. In Proceedings of the Fourth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge, Tennessee, 1985, edited by A. T. Schlafke-Stelson and E. E. Watson (Springfield, VA: National Technical Information Service), pp. 13-25.
2. AKABOSHI, M., KAWAI, K., MAKI, H., AKUTA, K., UJENO, Y., ONO, K. and MIYAHARA, T., 1993, Determination of the target volume of HeLa cells treated with platinum-195m radiolabeled trans-diaminedichloroplatinum(II): a comparison with cis-diaminedichloroplatinum(II). Nuclear Medicine and Biology, 20, 389-393.
3. 1-octreotide. The Journal of Nuclear Medicine, 37, 2002-2006.
4. AUGER, P., 1925, Sur les rayons β secondaires produits dans un gaz par des rayons X. Comptes Rendues Hebdomadaires des Seances de l'Academie des Sciences, 180, 65-68.
5. AZURE, M. T., SASTRY, K. S. R., ARCHER, R. D., HOWELL, R. W. and RAO, D. V., 1992, Microscale synthesis of carboplatin labeled with the Auger emitter platinum-193m: radiotoxicity versus chemotoxicity of the antitumor drug in mammalian cells. In Biophysical Aspects of Auger Processes, American Association of Physicists in Medicine Symposium Series No 8, edited by R. W. Howell, V. R. Narra, K. S. R. Sastry and D. V. Rao (Woodbury, NY: American Institute of Physics), pp. 336-351.
6. 125IUdR) by resistant cancer. The British Journal of Radiology, 64, 37-44.
7. 123I] iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model. International Journal of Radiation Oncology, Biology, Physics, 21, 1541-1551.
8. 131I-labeled CO17-1A in a human colorectal cancer model. International Journal of Cancer, 76, 738-748.
9. BEHR, T. M., BÉHÉ, M., LÖHR, M., SGOUROS, G., ANGERSTEIN, C., WEHRMANN, E., NEBENDAHL, K. and BECKER, W., 2000, Therapeutic advantages of Auger electron- over β-emitting radiometals or radioiodine when conjugated to internalizing antibodies. European Journal of Nuclear Medicine, 27, 753-765.
10. BISHAYEE, A., RAO, D. V., BOUCHET, L. G., BOLCH, W. E. and HOWELL, R. W., 2000a, Protection by DMSO against cell death caused by intracellularly localized iodine-125, iodine-131 and polonium-210. Radiation Research, 153, 416-427.
11. BISHAYEE, A., RAO, D. V. and HOWELL, R. W., 2000b, Radiation protection by cysteamine against the lethal effects of intracellularly localized Auger electron, α- and β-particle emitting radionuclides. Acta Oncologica, 39, 713-720.
12. BLOOMER, W. D. and ADELSTEIN, S. J., 1975, Antineoplastic effect of iodine-125-labelled iododeoxyuridine. International Journal of Radiation Biology, 27, 509-511.
13. 125I- iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature, 265, 620-621.
14. BLOOMER, W. D., MCLAUGHLIN, W. H., WEICHSELBAUM, R. R., TONNESEN, G. L., HELLMAN, S., SEITZ, D. E., HANSON, R. N., ADELSTEIN, S. J., ROSNER, A. L., BURSTEIN, N. A., NOVE, J. J. and LITTLE, J. B., 1980, Iodine-125-labelled tamoxifen is differentially cytotoxic to cells containing oestrogen receptors. International Journal of Radiation Biology, 38, 197-202.
15. BLOOMER, W. D., MCLAUGHLIN, W. H., MILIUS, R. A., WEICHSELBAUM, R. R. and ADELSTEIN, S. J., 1983, Estrogen receptor-mediated cytotoxicity using iodine-125. Journal of Cellular Biochemistry, 21, 39-45.
16. BRADLEY, E. W., CHAN, P. C. and ADELSTEIN, S. J., 1975, The radiotoxicity of iodine-125 in mammalian cells I. Effects on the survival curve of radioiodine incorporated into DNA. Radiation Research, 64, 555-563.
17. BRADY, L. W., MIYAMOTO, C., WOO, D. V., RACKOVER, M., EMRICH, J., BENDER, H., DADPARVAR, S., STEPLEWSKI, Z., KOPROWSKI, H., BLACK, P., LAZZARO, B., NAIR, S., MCCORMACK, T., NIEVES, J., MORABITO, M. and ESHLEMAN, J., 1992, Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. International Journal of Radiation Oncology, Biology, Physics, 22, 225-230.
18. 3 derivatives of octreotide in rats. Anticancer Research, 18, 83-89.
19. 125I in cell DNA at -196°C. International Journal of Radiation Biology, 24, 363-375.
20. CALABRESI, P., CARDOSO, S. S., FINCH, S. C., KLIGERMAN, M. M., VON ESSEN, C. F., CHU, M. Y. and WELCH, A. D., 1961, Initial clinical studies with 5-iodo-2′-deoxyuridine. Cancer Research, 21, 550-559.
21. 125. The Journal of Chemical Physics, 38, 2930-2934.
22. 3HTdR. Radiation Research, 67, 332-343.
23. 125I-UdR in cultured mammalian cells. Current Topics in Radiation Research Quarterly, 12, 426-435.
24. 125I. Radiation Research, 87, 10-23.
25. 125I decays. Radiation Research, 107, 163-171.
26. CHARLTON, D. E., POMPLUN, E. and BOOZ, J., 1987, Some consequences of the Auger effect: fluorescence yield, charge potential, and energy imparted. Radiation Research, 111, 553-564.
27. 125I. International Journal of Radiation Biology, 53, 353-365.
28. 111In-DTPA-hEGF, chemotherapeutic agents and γ-radiation on EGFR-positive breast cancer cells. Nuclear Medicine and Biology, 29, 693-699.
29. 111In-labeled epidermal growth factor administered to athymic mice bearing epithelial growth factor receptor-positive human breast cancer xenografts. The Journal of Nuclear Medicine, 44, 1469-1478.
30. COLE, A., 1969, Absorption of 20-eV to 50,000-eV electron beams in air and plastic. Radiation Research, 38, 7-33.
31. COMMERFORD, S. L. and JOEL, D. D., 1979, Iododeoxyuridine administered to mice is de-iodinated and incorporated into DNA primarily as thymidylate. Biochemical and Biophysical Research Communications, 86, 112-118.
32. 3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. International Journal of Cancer, 75, 406-411.
33. 125I-labeled monoclonal antibody 425 against cancer cells containing epidermal growth factor receptor. American Journal of Clinical Oncology, 15, 288-294.
34. DESOMBRE, E. R., MEASE, R. C., HUGHES, A., HARPER, P. V., DEJESUS, O. T. and FRIEDMAN, A. M., 1988, Bromine-80m-labeled estrogens: Auger electron-emitting, estrogen receptor-directed ligands with potential for therapy of estrogen receptor-positive cancers. Cancer Research, 48, 899-906.
35. 123I] iodovinyl-11β-methoxyestradiol and CHO-ER cells. In Biophysical Aspects of Auger Processes, American Association of Physicists in Medicine Symposium Series No 8, edited by R. W. Howell, V. R. Narra, K. S. R. Sastry and D. V. Rao (Woodbury, NY: American Institute of Physics), pp. 352-371.
36. DESOMBRE, E. R., HUGHES, A., LANDEL, C. C., GREENE, G., HANSON, R. and SCHWARTZ, J. L., 1996, Cellular and subcellular studies of the radiation effects of Auger electron-emitting estrogens. Acta Oncologica, 35, 833-840.
37. DESOMBRE, E. R., HUGHES, A., HANSON, R. N. and KEARNEY, T., 2000, Therapy of estrogen receptor-positive micrometastases in the peritoneal cavity with Auger electron-emitting estrogens: theoretical and practical considerations. Acta Oncologica, 39, 659-666.
38. ECKELMAN, W. C., KUBOTA, H., SIEGEL, B. A., KOMAI, T., RZESZOTARSKI, W. J. and REBA, R. C., 1976, Iodinated bleomycin: an unsatisfactory radiopharmaceutical for tumor localization. The Journal of Nuclear Medicine, 17, 385-388.
39. EIDINOFF, M. L., CHEONG, L. and RICH, M. A., 1959, Incorporation of unnatural pyrimidine bases into deoxyribonucleic acid of mammalian cells. Science, 129, 1550-1551.
40. 125I]iodovinyl- 11β-methoxyestradiol in MCF-7 human breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology, 39, 729-734.
41. FEIGE, Y. and GAVRON, A., 1975, Microdosimetry of Auger electrons. In Microdosimetry in Radiation Research: Biomedical, Chemical, and Physical Perspectives, edited by O. F. Nygaard, H. I. Adler and W. K. Sinclair (New York: Academic Press), pp. 557-569.
42. FEINENDEGEN, L. E., 1975, Biological damage from the Auger effect, possible benefits. Radiation and Environmental Biophysics, 12, 85-99.
43. FRONT, D., ISRAEL, O., IOSILEVSKY, G., EVEN-SAPIR, E., FRENKEL, A., PELEG, H., STEINER, M., KUTEN, A. and KOLODNY, G. M., 1987, Human lung tumors: Spect quantitation of differences in Co-57 bleomycin uptake. Radiology, 165, 129-133.
44. FRONT, D., ISRAEL, O., IOSILEVSKY, G., EVEN-SAPIR, E., FRENKEL, A., KOLODNY, G. M. and FEINSOD, M., 1988, SPECT quantitation of cobalt-57 bleomycin delivery to human brain tumors. The Journal of Nuclear Medicine, 29, 187-194.
45. GARRETT, C., WATAYA, Y. and SANTI, D. V., 1979, Thymidylate synthetase. Catalysis of dehalogenation of 5-bromo- and 5-iodo-2′-deoxyuridylate. Biochemistry, 18, 2798-2804.
46. 111In-labeled bleomycin for tumor localization by scintiscanning (abstract). The Journal of Nuclear Medicine, 14, 401.
47. GOVINDAN, S. V., GOLDENBERG, D. M., ELSAMRA, S. E., GRIFFITHS, G. L., ONG, G. L., BRECHBIEL, M. W., BURTON, J., SGOUROS, G. and MATTES, M. J., 2000, Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with β-particle emitters. The Journal of Nuclear Medicine, 41, 2089-2097.
48. GRIFFITHS, G. L., GOVINDAN, S. V., SGOUROS, G., ONG, G. L., GOLDENBERG, D. M. and MATTES, M. J., 1999, Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies. International Journal of Cancer, 81, 985-992.
49. GROVE, R. B., ECKELMAN, W. C. and REBA, R. C., 1973, Distribution of labeled bleomycin in normal and tumor-bearing mice. The Journal of Nuclear Medicine, 14, 917-919.
50. GROVE, R. B., REBA, R. C., ECKELMAN, W. C. and GOODYEAR, M., 1974, Clinical evaluation of radiolabeled bleomycin (blco) for tumor detection. The Journal of Nuclear Medicine, 15, 386-390.
51. 131 in the mouse and rat. Cancer Research, 21, 345-352.
52. 127I] iodoHoechst 33342: synthesis, DNA binding, and biodistribution. Journal of Medicinal Chemistry, 39, 4804-4809.
53. 125I-iododeoxy- uridine. Journal of the National Cancer Institute, 43, 763-773.
54. 131iodine. Radiation Research, 47, 94-109.
55. 3H: nuclear versus cytoplasmic radiation effects in murine L1210 leukaemia. International Journal of Radiation Biology, 28, 225-241.
56. 125I decays. International Journal of Radiation Biology, 64, 205-216.
57. 125I decays in DNA: effect of cysteamine on micronucleus formation and cell killing. Radiation Research, 141, 183-192.
58. 3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology, 136, 3698-3706.
59. 3]octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radioguided surgery. Proceedings of the Association of American Physicans, 111, 63-69.
60. 111Inbleomycin complex for tumor imaging: preparation, stability, and distribution in glioma-bearing mice. Journal of Surgical Oncology, 25, 168-175.
61. 111In-bleomycin complex for combined radiotherapy and chemotherapy. Journal of Surgical Oncology, 29, 91-98.
62. HOWELL, R. W., SASTRY, K. S. R., HILL, H. Z. and RAO, D. V., 1986, Cis-platinum-193m: its microdosimetry and potential for chemo-Auger combination therapy of cancer. In Proceedings of the Fourth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge, Tennessee, 1985, edited by A. T. Schlaike-Stelson and E. E. Watson (Springfield, VA: National Technical Information Service), pp. 493-513.
63. HOWELL, R. W., 1992, Radiation spectra for Auger-electron emitting radionuclides: Report No. 2 of AAPM Nuclear Medicine Task Group No. 6. Medical Physics, 19, 1371-1383.
64. HOWELL, R. W., KASSIS, A. I., ADELSTEIN, S. J., RAO, D. V., WRIGHT, H. A., HAMM, R. N., TURNER, J. E. and SASTRY, K. S. R., 1994, Radiotoxicity of platinum-195m-labeled trans-platinum (II) in mammalian cells. Radiation Research, 140, 55-62.
65. 125I. Micron, 33, 127-132.
66. HUMM, J. L., 1984, The analysis of Auger electrons released following the decay of radioisotopes and photoelectric interactions and their contribution to energy deposition (Jülich: Institut für Medizin, Kernforschungsanlage).
67. HUMM, J. L. and CHARLTON, D. E., 1988, Double strand breakage in DNA produced by the photoelectric interaction with incorporated 'cold' bromine. In DMA Damage by Auger Emitters, edited by K. F. Baverstock and D. E. Charlton (London: Taylor and Francis), pp. 111-122.
68. HUMM, J. L. and CHARLTON, D. E., 1989, A new calculational method to assess the therapeutic potential of Auger electron emission. International Journal of Radiation Oncology, Biology, Physics, 17, 351-360.
69. JÄÄSKELÄ-SAARI, H. A., KAIREMO, K. J. A., RAMSAY, H. A. and GRÉNMAN, R., 1998, Labelling of bleomycin with Auger-emitter increases cytotoxicity in squamous-cell cancer cell lines. International Journal of Radiation Biology, 73, 565-570.
70. 1]-octreotide in patients with neuroendocrine tumors: evaluation of therapeutic and toxic effects. Acta Oncologica, 38, 373-377.
71. 1]-octreotide in patients with neuroendocrine tumors. The Journal of Nuclear Medicine, 41, 1514-1518.
72. KAIREMO, K. J. A., RAMSAY, H. A., PAAVONEN, T. K., JÄÄ SKELÄSAARI, H. A., TAGESSON, M., LJUNGGREN, K. and STRAND, S.-E., 1997, Biokinetics of indium-111-bleomycin complex in head and neck cancer - implementations for radiochemotherapy. Cancer Detection and Prevention, 21, 83-90.
73. 125I-decay in a synthetic oligodeoxynucleotide: fragment distribution and evaluation of DMSO protection effect. Acta Oncologica, 35, 803-808.
74. 125I-labelled DNA ligand. Acta Oncologica, 39, 681-685.
75. 35S: theory and application to a cellular model. Radiation Research, 84, 407-425.
76. KASSIS, A. I., ADELSTEIN, S. J., HAYDOCK, C., SASTRY, K. S. R., MCELVANY, K. D. and WELCH, M. J., 1982, Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. Radiation Research, 90, 362-373.
77. KASSIS, A. I., ADELSTEIN, S. J., HAYDOCK, C. and SASTRY, K. S. R., 1983, Thallium-201: an experimental and a theoretical radiobiological approach to dosimetry. The Journal of Nuclear Medicine, 24, 1164-1175.
78. KASSIS, A. I., SASTRY, K. S. R. and ADELSTEIN, S. J., 1985, Intracellular distribution and radiotoxicity of chromium-51 in mammalian cells: Auger-electron dosimetry. The Journal of Nuclear Medicine, 26, 59-67.
79. 125I in mammalian cells. Radiation Research, 111, 305-318.
80. 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiation Research, 109, 78-89.
81. KASSIS, A. I., HOWELL, R. W., SASTRY, K. S. R. and ADELSTEIN, S. J., 1988, Positional effects of Auger decays in mammalian cells in culture. In DNA Damage by Auger Emitters, edited by K. F. Baverstock and D. E. Charlton (London: Taylor and Francis), pp. 1-13.
82. 125I-labeled DNA intercalator in mammalian cells. Radiation Research, 118, 283-294.
83. KASSIS, A. I., MAKRIGIORGOS, G. M. and ADELSTEIN, S. J., 1990a, Dosimetric considerations and therapeutic potential of Auger electron emitters. In Frontiers in Nuclear Medicine: Dosimetry of Administered Radionuclides, Proceedings of Symposium, 1989, edited by S. J. Adelstein, A. I. Kassis and R. W. Burt (Washington, DC: American College of Nuclear Physicians), pp. 257-274.
84. 125I]iodo- 2′-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans. Cancer Research, 50, 5199-5203.
85. KASSIS, A. I. and ADELSTEIN, S. J., 1993, Therapeutic potential of internally administered radionuclides. In Contemporary Issues in Neurological Surgery. Astrocytomas: Diagnosis, Treatment, and Biology, edited by P. McL Black, W. C. Schoene and L. A. Lampson (Boston: Blackwell Scientific Publications, Incorporated), pp. 290-299.
86. 125I/]iodo- 2′-deoxyuridine in the radiotherapy of solid CNS tumors in rats. Acta Oncologica, 35, 935-939.
87. 125I]iodo-2′-deoxyuridine in a patient with a brain tumor. The Journal of Nuclear Medicine, 37(4, suppl.), 19S-22S.
88. 125I]iodo- 2′-deoxyuridine in the radiotherapy of brain tumors in rats. The Journal of Nuclear Medicine, 39, 1148-1154.
89. KASSIS, A. I., HARAPANHALLI, R. S. and ADELSTEIN, S. J., 1999a, Strand breaks in plasmid DNA after positional changes of Auger electron-emitting iodine-125: direct compared to indirect effects. Radiation Research, 152, 530- 538.
90. KASSIS, A. I., HARAPANHALLI, R. S. and ADELSTEIN, S. J., 1999b, Comparison of strand breaks in plasmid DNA after positional changes of Auger electron-emitting iodine-125. Radiation Research, 151, 167-176.
91. 125I]iodo- 2′-deoxyuridine. Acta Oncologica, 39, 731-737.
92. 125I decay: effects of DNA conformation. Acta Oncologica, 39, 721-726.
93. 125I]iodo-2′-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis. The Journal of Nuclear Medicine, 44(5, suppl.), 35P-36P.
94. 125I]iodo- 2′-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis. International Journal of Radiation Biology, 80, 941-946.
95. KEARNEY, T., HUGHES, A., HANSON, R. N. and DESOMBRE, E. R., 1999, Radiotoxicity of Auger electron-emitting estrogens in MCF-7 spheroids: a potential treatment for estrogen receptor-positive tumors. Radiation Research, 151, 570-579.
96. 125I]iodo-6-aminoacridine. Nuclear Medicine and Biology, 17, 341-346.
97. 125I damage in mammalian cells. International Journal of Radiation Biology, 28, 417-425.
98. 1]-octreotide: a case history. Annals of the New York Academy of Sciences, 733, 496-506.
99. 1]-octreotide. Italian Journal of Gastroenterology and Hepatology, 31(suppl. 2), S219-S223.
100. KRISCH, R. E. and LEY, R. D., 1974, Induction of lethality and DNA breakage by the decay of iodine-125 in bacteriophage T4. International Journal of Radiation Biology, 25, 21-30.
101. KRISCH, R. E. and SAURI, C. J., 1975, Further studies of DNA damage and lethality from the decay of iodine-125 in bacteriophages. International Journal of Radiation Biology, 27, 553-560.
102. 125I decay in rec+ and recA strains of Escherichia coli. International Journal of Radiation Biology, 29, 37-50.
103. 125I decay in microorganisms. Current Topics in Radiation Research Quarterly, 12, 355-368.
104. KRISCH, R. E., FLICK, M. B. and TRUMBORE, C. N., 1991, Radiation chemical mechanisms of single- and double-strand break formation in irradiated SV40 DNA. Radiation Research, 126, 251-259.
105. KRISS, J. P., TUNG, L. and BOND, S., 1962, The distribution and fate of iododeoxycytidine in the mouse and rat. Cancer Research, 22, 1257-1264.
106. KROHN, K. A., MEYERS, J. M., DENARDO, G. L. and DENARDO, S. J., 1977, Comparison of radiolabeled bleomycins and gallium citrate in tumor-bearing mice. The Journal of Nuclear Medicine, 18, 276-281.
107. 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. The Journal of Nuclear Medicine, 40, 762-767.
108. 195mPt. The Journal of Nuclear Medicine, 14, 191-195.
109. 125I-iododeoxyuridine as a cellular label for in vitro assays: kinetics of incorporation and toxicity. Journal of the National Cancer Institute, 51, 1551-1558.
110. 125I-labelled thyroid hormone in hormone-responsive cells. International Journal of Radiation Biology, 61, 639-653.
111. 125I]iodo-2′-deoxyuridine. Radiation Research, 118, 532-544.
112. 125i]iodo-2′-deoxyuridine injected intratumorally in patients with gastrointestinal or breast cancers. Journal of Nuclear Biology and Medicine, 36, 154-157.
113. MARIANI, G., CEI, A., GIULIANI, E., BARANOWSKA-KORTYLEWICZ, J., COLLECCHI, P., DI STEFANO, R., MEUCCI, G., VIACAYA, P., DI LUCA, L., VAN DEN ABBEELE, A. D., BEVILACQUA, G., ADELSTEIN, S. J. and KASSIS, A. I., 1992b, Tumor targeting potential of 5-[I-125]iodo-2′-deoxyuridine injected intratumorally in patients with gastrointestinal or breast cancers. European Journal of Nuclear Medicine, 19, 705.
114. MARIANI, G., CEI, A., COLLECCHI, P., BARANOWSKA-KORTYLEWICZ, J., VAN DEN ABBEELE, A. D., DI LUCA, L., DI STEFANO, R., VIACAVA, P., FERDEGHINI, E. M., DI SACCO, S., SALVADORI, P. A., BEVILACQUA, G., ADELSTEIN, S. J., MOSCA, F. and KASSIS, A. I., 1993a, Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2'-deoxyuridine following intratumoral injection in patients with colorectal cancer. The Journal of Nuclear Medicine, 34, 1175-1183.
115. 125I]iodo-2′- deoxyuridine injected intratumorally in patients with breast cancer. Annals of the New York Academy of Sciences, 698, 204-211.
116. 123I]iodo-2′-deoxyuridine in patients with liver metastases from colon cancer. Journal of Nuclear Biology and Medicine, 37, 157-158.
117. 125i]iodo-2′-deoxyuridine in patients with breast cancer. In Radioactive Isotopes in Clinical Medicine and Research, edited by R. Hofer, H. Bergmann and H. Sinzinger (Stuttgart: Schattauer Verlag), pp. 188-193.
118. 123I]iodo-2′-deoxyuridine infused into the hepatic artery of patients with liver metastases from colorectal cancer. Journal of Nuclear Biology and Medicine, 38, 265-266.
119. 125I]iodo- 2′-deoxyuridine after intravesical infusion in patients with bladder cancer. The Journal of Nuclear Medicine, 37(4, suppl.), 16S-19S.
120. 123I]iodo-2′- deoxyuridine in patients with liver metastases from colorectal cancer. Acta Oncologica, 35, 941-945.
121. 123I]iodo-2′-deoxyuridine in patients with liver metastases from colorectal cancer. The Journal of Nuclear Medicine, 37(4, suppl.), 22S-25S.
122. MARIANI, G., BODEI, L., ADELSTEIN, S. J. and KASSIS, A. I., 2000, Emerging roles for radiometabolic therapy of tumors based on Auger electron emission. The Journal of Nuclear Medicine, 41, 1519-1521.
123. 125I-labeled DNA-binding compound that induces double-stranded DNA breaks. Cancer Research, 39, 3244-3247.
124. MARTIN, R. F. and HASELTINE, W. A., 1981, Range of radiochemical damage to DNA with decay of iodine-125. Science, 213, 896-898.
125. 125I]iodoestradiol in cultured MCF-7 human breast cancer
126. 125I]iodotamoxifen cytotoxicity in cultured human (MCF-7) breast cancer cells. Journal of Steroid Biochemistry, 33, 515-519.
127. 80mBr compounds for the study of Auger electron toxicity. Journal of Labelled Compounds and Radiopharmaceuticals, 29, 393-403.
128. MEYERS, M. O., ANTHONY, C. T., COY, D. H., MURPHY, W. A., DROUANT, G. J., FUSELIER, J., ESPENAN, G. D., MALONEY, T. J. and WOLTERING, E. A., 1998, Multiply radioiodinated somatostatin analogs induce receptor-specific cytotoxicity. Journal of Surgical Research, 76, 154-158.
129. 125I-bovine serum albumin. Radiation Research, 133, 182-186.
130. 125I-labelled Hoechst 33258 damage in six closely related DNA sequences. Journal of Molecular Biology, 203, 63-73.
131. NGUYEN, B. D. and ROARKE, M. C., 2000, Demonstration of non-small-cell lung carcinoma by indium-111 octreotide scintigraphy. Clinical Nuclear Medicine, 25, 814-816.
132. NIKJOO, H., MARTIN, R. F., CHARLTON, D. E., TERRISSOL, M., KANDAIYA, S. and LOBACHEVSKY, P., 1996, Modelling of Auger-induced DNA damage by incorporated I. Acta Oncologica, 35, 849-856.
133. NIKJOO, H., O'NEILL, P., GOODHEAD, D. T. and TERRISSOL, M., 1997, Computational modelling of low-energy electron-induced DNA damage by early physical and chemical events. International Journal of Radiation Biology, 71, 467-483.
134. 125I in triplex DNA. Acta Oncologica, 39, 707-712.
135. NIKJOO, H., BOLTON, C. E., WATANABE, R., TERRISSOL, M., O'NEILL, P. and GOODHEAD, D. T., 2002, Modelling of DNA damage induced by energetic electrons (100 eV to 100 keV). Radiation Protection Dosimetry, 99, 77-80.
136. OTTE, A., JERMANN, E., BEHE, M., GOETZE, M., BUGHER, H. C., ROSER, H. W., HEPPELER, A., MUELLER-BRAND, J. and MAECKE, H. R., 1997, DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. European Journal of Nuclear Medicine, 24, 792-795.
137. 125I labeled oligonucleotides. Nucleic Acids Research, 22, 4979-4982.
138. PANYUTIN, I. G. and NEUMANN, R. D., 1996, Sequence-specific DNA breaks produced by triplex-directed decay of iodine-125. Acta Oncologica, 35, 817-823.
139. 125I incorporated into a triplex-forming oligonucleotide correlates with geometry of the triplex. Nucleic Acids Research, 25, 883-887.
140. PANYUTIN, I. G., WINTERS, T. A., FEINENDEGEN, L. E. and NEUMANN, R. D., 2000, Development of DNA-based radiopharmaceuticals carrying Auger-electron emitters for anti-gene radiotherapy. The Quarterly Journal of Nuclear Medicine, 44, 256-267.
141. 125I in a triplex-forming oligonucleotide. Radiation Research, 156, 158-166.
142. 125I decay. Radiation Research, 115, 624-629.
143. POMPLUN, E., BOOZ, J. and CHARLTON, D. E., 1987, A Monte Carlo simulation of Auger cascades. Radiation Research, 111, 533-552.
144. POMPLUN, E., 2000, Auger electron spectra: the basic data for understanding the Auger effect. Acta Oncologica, 39, 673-679.
145. 125IUdR in cultured mouse BP8 tumour cells. British Journal of Cancer, 25, 594-597.
146. PRUSOFF, W. H., 1963, A review of some aspects of 5-iododeoxyuridine and azauridine. Cancer Research, 23, 1246-1259.
147. 57Co. European Journal of Nuclear Medicine, 4, 191-197.
148. 125I-induced DNA double strand breaks: use in calibration of the neutral filter elution technique and comparison with X-ray induced breaks. International Journal of Radiation Biology, 48, 555-566.
149. RAO, D. V., GOVELITZ, G. F. and SASTRY, K. S. R., 1983, Radiotoxicity of thallium-201 in mouse testes: inadequacy of conventional dosimetry. The Journal of Nuclear Medicine, 24, 145-153.
150. RAO, D. V., SASTRY, K. S. R., GOVELITZ, G. F., GRIMMOND, H. E. and HILL, H. Z., 1985, In vivo effects of iron-55 and iron-59 on mouse testes: biophysical dosimetry of Auger electrons. The Journal of Nuclear Medicine, 26, 1456-1465.
151. RAO, D. V., SASTRY, K. S. R., GRIMMOND, H. E., HOWELL, R. W., GOVELITZ, G. F., LANKA, V. K. and MYLAVARAPU, V. B., 1988, Cytotoxicity of some indium radiopharmaceuticals in mouse testes. The Journal of Nuclear Medicine, 29, 375-384.
152. 57Co-labeled bleomycin as a tumor-seeking agent. The Journal of Nuclear Medicine, 16, 1058-1069.
153. REGAUD, C. and LACASSAGNE, A., 1927, La radiosensibilité cellulaire envisagée dans ses manifestations générales. Radiophysiologie et Radiotherapie, 1, 95-116.
154. 2) - Part II. Preliminary results in patients with breast carcinoma. Nuclear Medicine and Biology, 19, 263-267.
155. 1 octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. Clinical Cancer Research, 5, 383-393.
156. RYAN, J. W., ROTMENSCH, J., PAN, M.-L., HARPER, P. V., GAILEY, S. J., DESOMBRE, E. R., STARK, V. and HERBST, A. L., 1989, Human biodistribution studies of a novel non-steroidal estrogen (I-123-IBHPE) (abstract). The Journal of Nuclear Medicine, 30, 883.
157. 125I]iodo- 2′-deoxyuridine in a raT model of leptomeningeal metastases. The Journal of Nuclear Medicine, 38, 386-390.
158. SASTRY, K. S. R. and RAO, D. V., 1984, Dosimetry of low energy electrons. In Physics of Nuclear Medicine: Recent Advances, edited by D. V. Rao, R. Chandra and M. C. Graham (Woodbury, NY: American Institute of Physics), pp. 169-208.
159. SCHMIDT, A. and HOTZ, G., 1973, The occurrence of double-strand breaks in coliphage T1-DNA by iodine-125 decay. International Journal of Radiation Biology, 24, 307-313.
160. SCHWARTZ, J. L., MUSTAFI, R., HUGHES, A. and DESOMBRE, E. R., 1996, DNA and chromosome breaks induced by iodine-123-labeled estrogen in Chinese hamster ovary cells. Radiation Research, 146, 151-158.
161. SEDELNIKOVA, O. A., PANYUTIN, I. G., THIERRY, A. R. and NEUMANN, R. D., 1998, Radiotoxicity of iodine-125-labeled oligodeoxyribonucleotides in mammalian cells. The Journal of Nuclear Medicine, 39, 1412-1418.
162. 125I-labeled triplex-forming oligonucleotides. Antisense and Nucleic Acid Drug Development, 10, 443-452.
163. SEDELNIKOVA, O. A., LUU, A. N., KARAMYCHEV, V. N., PANYUTIN, I. G. and NEUMANN, R. D., 2001, Development of DNA-based radiopharmaceuticals carrying Auger-electron emitters for antigene radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 49, 391-396.
164. 125I]metaiodobenzylguanidine. Journal of Nuclear Biology and Medicine, 35, 255-259.
165. 195mPt-cis-dichlorodiammine platinum (II) in man. The Journal of Nuclear Medicine, 15, 349-351.
166. SNELLING, L., MIYAMOTO, C. T., BENDER, H., BRADY, L. W., STEPLEWSKI, Z., CLASS, R., EMRICH, J. and RACKOVER, M. A., 1995, Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Hybridoma, 14, 111-114.
167. STEPANEK, J., LARSSON, B. and WEINREICH, R., 1996, Auger-electron spectra of radionuclides for therapy and diagnostics. Acta Oncologica, 35, 863-868.
168. 114mIn. Acta Oncologica, 39, 667-671.
169. THAKUR, M. L., 1973, The preparation of indium-111 labelled bleomycin for tumour localisation. International Journal of Applied Radiation and Isotopes, 24, 357-359.
170. 1-octreotide. Nuclear Medicine and Biology, 27, 183-188.
171. 0] octreotide: the Rotterdam experience. Seminars in Nuclear Medicine, 32, 110-122.
172. VIRGOLINI, I., SZILVASI, I., KURTARAN, A., ANGELBERGER, P., RADERER, M., HAVLIK, E., VORBECK, F., BISCHOF, C., LEIMER, M., DORNER, G., KLETTER, K., NIEDERLE, B., SCHEITHAUER, W. and SMITHJONES, P., 1998, Indium-111-DOTA- lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. The Journal of Nuclear Medicine, 39, 1928-1936.
173. WALICKA, M. A., ADELSTEIN, S. J. and KASSIS, A. I., 1998a, Indirect mechanisms contribute to biological effects produced by decay of DNA-incorporated iodine-125 in mammalian cells in vitro: double-strand breaks. Radiation Research, 149, 134-141.
174. WALICKA, M. A., ADELSTEIN, S. J. and KASSIS, A. I., 1998b, Indirect mechanisms contribute to biological effects produced by decay of DNA-incorporated iodine-125 in mammalian cells in vitro: clonogenic survival. Radiation Research, 149, 142-146.
175. 125I]iodoHoechst 33342: contribution of scavengeable effects. International Journal of Radiation Biology, 75, 1579-1587.
176. WALICKA, M. A., DING, Y., ADELSTEIN, S. J. and KASSIS, A. I., 2000, Toxicity of DNA-incorporated iodine-125: quantifying the direct and indirect effects. Radiation Research, 154, 326-330.
177. 125I]iodo-2′-deoxyuridine toxicity in mammalian cells in vitro. International Journal of Radiation Biology, 77, 625-630.
178. WARTERS, R. L. and HOFER, K. G., 1977, Radionuclide toxicity in cultured mammalian cells: elucidation of the primary site for radiation-induced division delay. Radiation Research, 69, 348-358.
179. 125iodoacetylproflavine, a DNA-intercalating agent, in human cells. International Journal of Radiation Biology, 57, 1087-1103.
180. XUE, L. Y., BUTLER, N. T., MAKRIGIORGOS, G. M., ADELSTEIN, S. J. and KASSIS, A. I., 2002, Bystander effect produced by radiolabeled tumor cells in vivo. Proceedings of the National Academy of Sciences of the United States of America, 99, 13765-13770.
181. 125I-estrogen. Acta Oncologica, 35, 841-847.
182. 125I-estrogen decays in estrogen receptor-expressing MCF-7 human breast cancer cells. Radiation Research, 155, 328-334.
183. 125I-oestrogen decay in non-oestrogen receptor-expressing human breast cancer cells, MDA-231 and oestrogen receptor-expressing MCF-7 cells. International Journal of Radiation Biology, 77, 955-962.